PubMed Health⌕ Search

Biomedical subjects

Z Mitchla

Publications and source records attributed to Z Mitchla.

3 recordsLinked to original sources

Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission.

AIMS OF THE GUIDELINES: These guidelines, drawn up by a multidisciplinary group of clinicians and lay workers active in the management of pregnant women infected with HIV, aim to give up-to-date information on interventions to reduce the risk of mother to child transmission of the virus. The evidence on the use of interventions to prevent mother to child transmission of HIV has been graded according to the strength of the data as per the definitions of the US Agency for Health Care Policy and Research [1]. Weighted evidence on the use of combination antiretroviral therapy (ART) for the treatment of HIV infection per se is presented in the BHIVA guidelines for adults [2,3]. The highest level evidence (i.e. randomised controlled trials (RCTs) or large, well conducted meta-analyses) is only available for formula feeding, prelabour caesarean section and zidovudine monotherapy. The need to treat mothers for HIV infection has led to the widespread use of ART in pregnancy which in turn results in new questions such as how to deliver when the mother, on therapy, has no detectable plasma viraemia with the most sensitive assays. In addressing many common and/or difficult clinical scenarios in the absence of 'best evidence' the guidelines rely heavily on 'expert opinion'. Recommendations for management are given in the section on clinical scenarios, and summarized in Table 3. An expanded version of these guidelines with an appendix on safety and toxicity data is available on the BHIVA website http://www.bhiva.org. The authors are available to discuss individual cases.

Adult↗

Current treatment options to prevent perinatal transmission of HIV.

Mother-to-infant transmission is the primary means by which young children become infected with HIV. WHO estimates approximately 1600 infants become infected with HIV every day. Recent advances in identifying the factors determining perinatal transmission have allowed interventions to be made to reduce mother-infant transmission. Paediatric AIDS Clinical Trials Group (PACTG) protocol 076, the pivotal vertical transmission study demonstrated that zidovudine (AZT) in pregnancy could reduce perinatal transmission of HIV-1 by 67%. This was confirmed by PACTG 185, in pregnant women with more advanced disease, which also demonstrated that viral load was the only independent factor determining vertical transmission rate (VTR). More recently, results from several short-course antiretroviral trials have brought new hope, that effective preventative interventions can be extended to developing countries. Although most studies have involved shorter versions of PACTG 076, the latest finding from HIVNET 012 demonstrated a significant reduction in VTR using a two-dose regimen of nevirapine (NVP). This intervention is the simplest, least expensive regimen so far with proven efficacy in diminishing mother-infant transmission. Non-pharmacological interventions have also been studied recently. The benefits of elective caesarean section (ELCS) have been clearly demonstrated in recent studies. These studies were carried out at a time when highly active antiviral therapies (HAART) were not available. There is still no information as to whether ELCS provides any added benefit for women on HAART with an undetectable HIV viral load. Prevention of breastfeeding can also further reduce VTR. This strategy is more applicable to resource-rich countries where access to formula feeds is not a problem. Options to prevent perinatal transmission must take into consideration the economic climate in which the intervention is to be made. In developed countries, effective intervention with perinatal AZT, ELCS and exclusive formula feeding has already reduced the VTR to around 1%. There is limited safety data currently available on the use of other antiretrovirals in pregnancy. A cautious approach to the use of HAART in pregnancy is recommended at present.

Adult↗